AFIB Ablation denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for afib ablation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on AFIB Ablation
## Why Humana Denied Catheter Ablation for AFib as Duplicate Therapy
Humana may issue a duplicate-therapy denial for catheter ablation when your records show you are currently prescribed one or more antiarrhythmic medications. The plan's logic is that ablation and ongoing rhythm-control drugs are addressing the same problem, making one of them redundant. This framing misunderstands how ablation fits into AF management: ablation is a structural intervention intended to eliminate the arrhythmia's source, not simply to suppress symptoms alongside existing medication. When medication has already been tried and failed — or when your cardiologist recommends ablation as an appropriate next step in your specific clinical situation — ablation is a distinct and non-duplicative intervention.
## Why This Denial Is Appealable
A duplicate-therapy determination requires the plan to demonstrate that the two treatments are clinically interchangeable and that continued use of both is not medically justified. Ablation and antiarrhythmic drug therapy are not interchangeable: they act through entirely different mechanisms and serve different clinical goals. Major professional societies — including the Heart Rhythm Society (HRS) and the American Heart Association/American College of Cardiology (AHA/ACC) — publish guidelines describing specific patient profiles for whom catheter ablation is an appropriate and indicated treatment strategy. If your clinical situation fits those profiles, the denial lacks clinical foundation.
## Federal Appeal Rights
You have the right to appeal this denial through two parallel tracks:
- Internal Appeal: Submit a written appeal to Humana within the timeframe stated in your denial letter (typically 180 days for a standard internal appeal). Humana must review and respond within regulatory deadlines.
- External Review: If the internal appeal is denied or if the denial qualifies as an urgent matter, you may request an independent external review under ACA Section 2719. An accredited Independent Review Organization (IRO) — not affiliated with Humana — will assess whether the denial is consistent with accepted medical standards. You generally have up to four months from an adverse benefit determination to file for external review. An expedited external review is available if your condition is serious or your health is at risk from delay.
- ERISA Protections: If your coverage is through an employer-sponsored plan, ERISA Section 503 guarantees you a full-and-fair review, including the right to request the complete claim file and all criteria used in the decision.
## Documentation to Gather
- Cardiology records confirming your AFib diagnosis, type, and duration
- Complete medication history: every antiarrhythmic tried, with start/stop dates and documented reason for discontinuation (side effects, inadequate rhythm control, recurrence)
- Electrophysiology (EP) consultation notes recommending ablation and explaining medical necessity
- ECGs, Holter monitor results, or event-monitor data documenting ongoing or recurrent arrhythmia
- A detailed medical-necessity letter from your EP specialist explaining why ablation is a distinct, non-duplicative intervention for your specific situation
## Criteria-Mapping Strategy
Request Humana's complete coverage policy for catheter ablation. Copy each criterion listed. For each one, identify the corresponding entry in your medical record. A table format works well:
| Humana Criterion | Supporting Chart Evidence | |---|---| | Diagnosis confirmed | [EP note date, ECG report] | | Trial-and-failure of antiarrhythmic drug(s) | [Medication list with dates and outcomes] | | Ablation not duplicating existing therapy | [EP letter explaining distinct mechanism] |
Present this mapping at the front of your appeal letter so the reviewer can verify compliance with every criterion without searching.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →